article thumbnail

Building agile partner relationships at a vaccine-focused biotech

pharmaphorum

In this episode of the pharmaphorum podcast series, Dr Paul Tunnah chats with Jeff Baxter, CEO of VBI Vaccines and Lee Taurman, executive vice president full service commercial at Syneos Health. Jeff Baxter – President and CEO, VBI Vaccines. Whitman School of Management at Syracuse University.

article thumbnail

HIV vaccines suffer setbacks but new approaches could turn the tide

Pharmaceutical Technology

Only a few weeks into the new year, the prospect of getting a successful advanced HIV vaccine shrank after the discontinuation of yet another late-stage trial. On January 18, Janssen, a Johnson & Johnson (J&J) subsidiary, stated that its vaccine was not effective in preventing HIV infections.

Vaccines 117
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

3 steps for comprehensive patient collaboration

pharmaphorum

In 2006 he joined the Janssen teams working in Infectious Diseases where he helped to maintain and enhance the company’s relationships with the HIV Patient Community. Later, he built the external relationships in the field of Hepatitis C, before becoming the Global Therapeutic Area Communications Leader Infectious Diseases and Vaccines.

article thumbnail

Biosimilars: a rapidly maturing market

pharmaphorum

The global health crisis caused spending on healthcare to increase , due to the funding provided to the development and purchases of vaccines and treatments, as well as support provided for the associated infrastructure. The short story so far.

article thumbnail

Record number of health firms feature in UK top 100 private tech list

pharmaphorum

There are pharma companies on the list, including Kymab , which at number 87 is working with the Bill & Melinda Gates Foundation to test several potential vaccines. Also on the list is Faculty, which at number 33 provides accurate and timely information used by decision-makers in the NHS and the government.

article thumbnail

A history of AstraZeneca

pharmaphorum

In June 2007, AstraZeneca completed the acquisition of vaccine maker MedImmune, buying its drug-development pipeline for $15.2 Having already acquired UK-based Cambridge Antibody Technology in 2006, AstraZeneca merged these two companies to create a dedicated global biologics organisation known as MedImmune.

Vaccines 116
article thumbnail

How can the pharma industry address the gap in talent recruitment and development?

pharmaphorum

The development of an effective COVID-19 vaccine has been universally recognised as our way out of the pandemic, and humanity has seen the tangible impact of vaccines saving countless lives on a massive, global scale. In addition, she worked as head of inspectorate and licensing for the MHRA from 2004-2006. appeared first on.